Business
Helix Biopharma Corp. Announces Fiscal 2023 Second Quarter Results
(TheNewswire) Toronto, O N - TheNewswire - March 15, 2023 - Helix B...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix Biopharma Corp. Announces Fiscal 2023 Second Quarter Results\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Toronto, O\n \n \n N\n \n \n -\n \n \n TheNewswire -\n \n \n March 15, 2023 -\n \n \n \n \n Helix BioPharma Corp.\n \n \n (TSX:HBP)\n \n \n ,\n(“\n \n \n Helix\n \n \n ” or the “\n \n \n Company\n \n \n ”), a clinical-stage\nbiopharmaceutical company developing unique therapies in the field of\nimmuno-oncology based on its proprietary technological platform DOS47,\ntoday announced financial results for the fiscal 2023 second quarter\nresults for the period ending January 31, 2023.\n \n \n \n \n OVERVIEW\n \n \n \n \n The Company reported a net loss and total comprehensive\nloss of $1,185,000 and $2,791,000 for the three and six-month periods\nended January 31, 2023, respectively (January 31, 2022 - $2,019,000\nand $3,832,000) and a loss of $0.01 and $0.01 per common share\nrespectively (January 31, 2022– loss of $0.01 and $0.02 per common\nshare).\n \n \n \n \n Clinical\ndevelopment\n \n \n \n \n LDOS47 in lung cancer\n \n \n \n \n \n \n The Phase I study combination therapy in lung cancer\n(LDOS001) was completed and a manuscript was accepted for publication\nin\n \n \n Journal of Thoracic\nOncology Clinical and Research Reports\n \n \n on\nSeptember 2\n \n \n nd\n \n \n , 2022. The full-text open access article can be found\nhere:\n \n \n \n \n https://www.jtocrr.org/article/S2666-3643(22)00132-1/fulltext\n \n \n \n \n \n \n \n \n \n \n The Phase II study of combination therapy in lung\ncancer (LDOS003) was halted in the dose escalation portion of the\nstudy in 2020 at the height of pandemic lockdown and the final\nabbreviated clinical trial report has been further delayed amidst war\nin Ukraine where all subjects were recruited. The company is\ncurrently working with study partners to retrieve any data that is\nsalvageable and conclude the study by end of the second quarter of\n2023.\n \n \n \n \n \n \n \n \n Another important aspect of the development of the\nLDOS47 platform is the combination with chemo- and/or\nimmuno-therapy to enhance current therapies, that may boost the\nutility of the platform. The Company continues to\n \n \n has\n \n \n engag\n \n \n ed\n \n \n several key opinion leaders to\nevaluate potential...